
|Videos|March 26, 2021
Dr. Swerdloff discusses the oral testosterone capsule Jatenzo
Author(s)Urology Times staff
Advertisement
Ronald S. Swerdloff, MD, MACP, discusses the approved indication and efficacy of Jatenzo (testosterone undecanoate), an oral testosterone capsule. Jatenzo is approved by the FDA as a testosterone replacement therapy for men with certain forms of hypogonadism. It is indicated for patients with low testosterone levels as a results of certain medical conditions, such as genetic disorders or cancer-related damage to their pituitary gland.
Swerdloff is a senior investigator at the Lundquist Institute, chief, Division of Endocrinology, Harbor-UCLA Medical Center, and professor of Medicine, David Geffen School of Medicine at UCLA.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
Matthew Galsky, MD, on how EV/pembrolizumab is redefining the MIBC treatment paradigm
2
Published BOND-003 data show durable responses with cretostimogene in NMIBC
3
Cretostimogene Grenadenorepvec: Mechanism and Rationale
4
Pearls & Perspectives: From Prostate Cancer Diagnosis to Patient Advocacy, with Gabe Canales
5












